---
TL;DR: BPC-157 research protocols typically reference 250–500 mcg subcutaneously once or twice daily, or 500–1,000 mcg orally (arginate form). For a 5 mg vial with 2.5 mL bacteriostatic water, each 0.1 mL = 200 mcg. Use our peptide dosage calculator to automate all vial math instantly.

What Is BPC-157 and Why Does Dosage Precision Matter?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a naturally occurring protein in human gastric juice. In preclinical research, it has demonstrated a remarkable range of tissue-protective effects β€” accelerating healing of tendons, ligaments, muscle tissue, peripheral nerves, and the gastrointestinal tract. Its mechanisms center on promoting angiogenesis via VEGF modulation, upregulating collagen synthesis, and exerting systemic anti-inflammatory effects.

Because BPC-157 is studied in microgram-level quantities, minor calculation errors can mean a 2Γ— or 4Γ— variance from the intended dose. A researcher working with a 5 mg vial and 2 mL of bacteriostatic water ends up with an entirely different concentration than one using 3 mL β€” and the injection volumes change accordingly. That's exactly why a reliable BPC-157 dosage calculator is an essential tool for any peptide research setup. Our peptide calculator handles all of this math automatically for any vial size or target dose.

Research Use Only: BPC-157 is not approved by the FDA for human use. All dosing information below reflects commonly referenced preclinical and early clinical research protocols for laboratory reference purposes only.

Understanding BPC-157 Concentrations: The Core Math

The fundamental formula for peptide concentration is straightforward:

Concentration (mcg/mL) = Total peptide (mcg) Γ· Reconstitution volume (mL)

From there, injection volume is derived by dividing your target dose by the concentration. The table below covers the most common vial sizes and reconstitution volumes referenced in research literature:

Vial Size Bacteriostatic Water Added Concentration Volume for 250 mcg Volume for 500 mcg
5 mg (5,000 mcg) 2.5 mL 2,000 mcg/mL 0.125 mL (12.5 units) 0.25 mL (25 units)
5 mg (5,000 mcg) 5.0 mL 1,000 mcg/mL 0.25 mL (25 units) 0.50 mL (50 units)
10 mg (10,000 mcg) 3.0 mL 3,333 mcg/mL 0.075 mL (7.5 units) 0.15 mL (15 units)
10 mg (10,000 mcg) 5.0 mL 2,000 mcg/mL 0.125 mL (12.5 units) 0.25 mL (25 units)
10 mg (10,000 mcg) 10.0 mL 1,000 mcg/mL 0.25 mL (25 units) 0.50 mL (50 units)

"Units" here refers to marks on a standard U-100 insulin syringe (where 100 units = 1 mL). Most peptide researchers use U-100 syringes for precision subcutaneous administration.

BPC-157 Concentration Formula VIAL SIZE 5 mg = 5,000 mcg 10 mg = 10,000 mcg Γ· BAC WATER (mL) 2.5 mL β†’ 2,000 mcg/mL 5.0 mL β†’ 1,000 mcg/mL = INJECTION VOLUME Target Dose Γ· Concentration 250 mcg Γ· 2,000 mcg/mL = 0.125 mL (12.5 units) U-100 syringe: 100 units = 1 mL. Use our /calculator for any vial size or dose.

For anyone who prefers not to do this manually, our peptide dosage calculator accepts your vial size, reconstitution volume, and target dose β€” and returns both the concentration and the exact injection volume in mL and syringe units.

BPC-157 Dosage Calculator: Common Research Protocols

Published preclinical literature and the limited available human pharmacokinetic data converge on two primary administration routes, each with distinct dosing parameters.

Subcutaneous Injection Protocol

The most widely referenced protocol in animal studies involves subcutaneous (SQ) injection, either near the site of injury (local) or abdominally (systemic). Key parameters from peer-reviewed preclinical studies include:

  • Dose range: 250–500 mcg per injection
  • Frequency: Once or twice daily
  • Duration: 4–12 weeks depending on research objective
  • Preferred form: BPC-157 acetate salt (standard lyophilized powder)

Oral Administration Protocol

BPC-157's arginate salt form exhibits greater stability through the gastrointestinal environment, making it the preferred form for oral administration studies β€” particularly those investigating GI repair mechanisms:

  • Dose range: 500–1,000 mcg daily
  • Duration: Typically 4 weeks
  • Form required: BPC-157 arginate salt specifically (not the standard acetate)

How to Use a BPC-157 Dosage Calculator Step by Step

  1. Confirm your vial size β€” typically 5 mg or 10 mg lyophilized powder
  2. Choose your reconstitution volume β€” enter how much bacteriostatic water you'll add
  3. Enter your target dose β€” e.g., 250 mcg or 500 mcg per injection
  4. Read the output β€” concentration in mcg/mL plus injection volume in both mL and U-100 syringe units
  5. Double-check your syringe β€” confirm the syringe is U-100 (not U-40 or U-50, which would shift all volume calculations)

Our peptide calculator handles steps 2–4 instantly and also supports other common research peptides including TB-500 and GHK-Cu.

Mechanism of Action: Why BPC-157 Works at Microgram Doses

BPC-157's potency at low doses is partly explained by its upstream positioning in several repair cascades. Its primary mechanisms include:

  • VEGF upregulation: BPC-157 promotes vascular endothelial growth factor expression, accelerating the formation of new blood vessels (angiogenesis) at injury sites. This is a critical bottleneck in tendon and ligament healing, where vascularity is naturally poor.
  • Collagen synthesis: Studies in rat models demonstrate upregulation of collagen synthesis gene expression, contributing to faster structural repair in connective tissue.
  • Nitric oxide modulation: BPC-157 appears to interact with the NO-system, influencing vasoprotection and reducing ischemia-reperfusion injury.
  • Growth hormone receptor sensitization: Some evidence suggests BPC-157 may enhance tissue responsiveness to endogenous growth factors without directly elevating GH levels.
  • Cytoprotective GI effects: Derived originally from gastric juice protein, BPC-157 has robust cytoprotective properties in gastric and intestinal epithelium, relevant to inflammatory bowel research models.
BPC-157 Mechanism of Action Overview BPC-157 15 amino acids VEGF Upregulation β†’ Angiogenesis Collagen Synthesis β†’ Tendon / Ligament NO Modulation β†’ Vasoprotection GI Cytoprotection β†’ Mucosal Repair GH Sensitization β†’ Growth Factor Response Preclinical mechanisms β€” human clinical data remains limited as of 2026

Reconstitution Protocol: Step-by-Step

Proper reconstitution preserves peptide integrity and ensures accurate dosing. The process requires bacteriostatic water (0.9% benzyl alcohol in sterile water), which is essential for multi-use vials β€” sterile water without benzyl alcohol supports only single-use reconstitution.

  1. Gather supplies: Lyophilized BPC-157 vial, bacteriostatic water, 1–3 mL syringe for reconstitution, alcohol swabs, U-100 insulin syringe for dosing
  2. Swab both vial tops with alcohol and allow to dry (30 seconds)
  3. Draw bacteriostatic water into the reconstitution syringe β€” use the volume from your dosage calculator calculation
  4. Inject slowly at an angle against the vial wall β€” do not inject directly onto the powder or forcefully agitate
  5. Gently swirl (do not shake) until the powder is fully dissolved and the solution is clear
  6. Label with date β€” reconstituted BPC-157 is typically stable for 4–8 weeks refrigerated at 2–8Β°C

A 10 mg vial reconstituted with 3.0 mL of bacteriostatic water yields a concentration of 3,333 mcg/mL β€” on the high end, which can make measuring small volumes (75 Β΅L for a 250 mcg dose) challenging without precise insulin syringes. Many researchers prefer adding 5–10 mL to achieve 2,000 or 1,000 mcg/mL for easier measurement. Use our peptide calculator to find which concentration makes your target dose easiest to measure accurately.

BPC-157 Research Stacks: Common Combinations

BPC-157 is frequently studied in combination with other peptides whose mechanisms may complement its tissue-repair activity:

BPC-157 + TB-500

TB-500 (Thymosin Beta-4) promotes actin polymerization and cell migration, acting on the early stages of tissue repair, while BPC-157 drives angiogenesis and collagen remodeling. The two are hypothesized to operate on complementary phases of the healing cascade. Research protocols typically run both concurrently over 4–6 weeks, with each dosed independently at their standard ranges.

BPC-157 + GHK-Cu

GHK-Cu (copper peptide) is studied for its role in skin and connective tissue regeneration, operating partly through metalloproteinase regulation and TGF-Ξ² signaling. Combined protocols with BPC-157 are explored in models where surface tissue repair (dermal, mucosal) is the primary endpoint.

Safety Profile and Side Effect Considerations

Across an extensive body of rodent and small animal research, BPC-157 has demonstrated a favorable safety profile with no reported toxic dose established in preclinical models. However, as of 2026, published human pharmacokinetic data remains extremely limited β€” a Phase 1 trial (NCT02637284) has completed but results are not yet published, and a Phase 2 hamstring injury trial (NCT07437547) is currently recruiting.

Notable areas of caution flagged in research literature and case-level observations include:

  • Serotonergic interactions: Some reports indicate potential mood-related effects β€” including anhedonia or anxiety β€” in subjects concurrently using SSRIs, SNRIs, or benzodiazepines. The proposed mechanism involves BPC-157's interaction with the dopaminergic and serotonergic systems. Researchers working with animal models on concurrent pharmacological regimens should monitor for behavioral changes.
  • Injection site reactions: Mild transient redness or discomfort at the subcutaneous injection site is occasionally noted, consistent with any SQ peptide administration.
  • Theoretical proliferative concern: Because BPC-157 upregulates VEGF and promotes angiogenesis, some researchers have raised theoretical questions about its study in models with pre-existing neoplastic conditions. No direct evidence of tumor promotion has been demonstrated, but it remains an area of protocol consideration.
Typical BPC-157 Research Protocol Timeline Wk 1 Reconstitute + Baseline Wk 2–4 250–500 mcg 1–2Γ— daily SQ Wk 5–8 Continue or Taper dose Wk 9–12 Assessment / Washout End GI-focused oral protocols: 500–1,000 mcg/day arginate form Β· typically 4 weeks Β· no injection required

Storage and Stability

Proper storage directly affects the accuracy of every dosage calculation β€” degraded peptide means your measured volume no longer reflects active compound:

  • Lyophilized (dry) powder: Store at βˆ’20Β°C for long-term stability (up to 24 months); short-term storage at 4Β°C acceptable for weeks
  • Reconstituted solution: Refrigerate at 2–8Β°C; typical stability window is 4–8 weeks with bacteriostatic water
  • Avoid: Repeated freeze-thaw cycles, direct UV light exposure, and agitation
  • Use sterile technique at every step β€” bacteriostatic water extends vial life but does not fully compensate for contamination introduced during handling

Clinical Trial Status (2026)

As of 2026, BPC-157 remains a research compound without FDA approval or equivalent regulatory clearance for human therapeutic use. Two notable trials are active in the registry:

  • NCT02637284 β€” Phase 1 safety and pharmacokinetics trial; completed, results unpublished
  • NCT07437547 β€” Phase 2 trial in hamstring injuries; currently recruiting participants

Researchers should consult ClinicalTrials.gov and current peer-reviewed literature for the most updated findings before designing any new study protocol.

Frequently Asked Questions

What concentration should I use when reconstituting a 5 mg BPC-157 vial?

A common approach is adding 2.5 mL of bacteriostatic water, yielding 2,000 mcg/mL β€” this makes a 250 mcg dose equal to 0.125 mL (12.5 units on a U-100 syringe), which is easily measurable. Adding 5.0 mL drops the concentration to 1,000 mcg/mL, making a 250 mcg dose 0.25 mL (25 units) β€” easier to measure but the vial depletes faster. Use our peptide calculator to find your ideal dilution.

What is the difference between BPC-157 acetate and BPC-157 arginate?

BPC-157 acetate is the standard form used for subcutaneous injection research. BPC-157 arginate (also called the stable gastric pentadecapeptide BPC 157) has greater stability in acidic environments, making it the appropriate form for oral administration studies focused on GI tissue repair. The two should not be used interchangeably in protocol design.

How does a BPC-157 dosage calculator work?

You input your vial size (e.g., 5 mg), the volume of bacteriostatic water you plan to add, and your target dose per injection (e.g., 250 mcg). The calculator divides total peptide by reconstitution volume to get concentration, then divides the target dose by that concentration to give you the exact mL and syringe units to draw. Our peptide calculator handles all three steps automatically.

Can BPC-157 be studied alongside TB-500 in the same protocol?

Yes β€” preclinical research has explored concurrent administration of BPC-157 and TB-500 based on their hypothesized complementary mechanisms (BPC-157 driving angiogenesis and collagen remodeling; TB-500 promoting cell migration and actin polymerization). Each peptide is dosed independently at its standard range; they are typically administered as separate injections rather than mixed in the same syringe.

How long is reconstituted BPC-157 stable in the refrigerator?

When reconstituted with bacteriostatic water and stored at 2–8Β°C away from light, BPC-157 solution is generally considered stable for 4–8 weeks. Sterile water (without benzyl alcohol) reduces this significantly to single-use or same-day use. Always label vials with the reconstitution date and discard at the first sign of cloudiness or particulates.

References

  1. Sikiric, P., Seiwerth, S., Rucman, R., et al. (2018). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 24(18), 1994–2003. Demonstrates cytoprotective and healing mechanisms across GI and musculoskeletal tissue in rodent models. View on PubMed
  2. Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 110(3), 774–780. Documents VEGF-mediated angiogenic effects and collagen synthesis upregulation in tendon repair models. View on PubMed
  3. Pevec, D., Novinscak, T., Brcic, L., et al. (2010). "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor, 16(3), BR81–88. Examines BPC-157 efficacy in a steroid-impaired muscle healing model, supporting the 10–15 mcg/kg dose range used in rodent studies. View on PubMed
  4. ClinicalTrials.gov. (2024). "BPC-157 Phase 1 Safety and Pharmacokinetics Study." Identifier NCT02637284. U.S. National Library of Medicine. View trial registry
  5. Peptide-DB.com. (2025). "BPC-157 Peptide Profile: Mechanisms, Dosing, and Research Overview." Summarizes published preclinical mechanism data including VEGF modulation, NO system interaction, and collagen synthesis pathways. View source